These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12171976)

  • 1. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea.
    Beales IL
    Gut; 2002 Sep; 51(3):456. PubMed ID: 12171976
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea.
    McPherson S; Rees CJ; Ellis R; Soo S; Panter SJ
    Dis Colon Rectum; 2006 May; 49(5):640-5. PubMed ID: 16525744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of recurrent Clostridium difficile diarrhoea using sequential therapy with vancomycin followed by rifaximin].
    Zelada Rodríguez MA; Rodríguez D; Martí X; Espejo E
    Rev Esp Geriatr Gerontol; 2012; 47(1):42-4. PubMed ID: 22105006
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of Clostridium difficile disease in patients not responding to metronidazole.
    Kapoor S
    J Infect; 2008 May; 56(5):394-5. PubMed ID: 18410968
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review.
    O'Horo J; Safdar N
    Int J Infect Dis; 2009 Nov; 13(6):663-7. PubMed ID: 19186089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of Clostridium difficile infections.
    Aldeyab MA; McElnay JC; Scott MG; Davies E; Edwards C; Darwish Elhajji FW; Conlon G; Magee FA; Barr PJ; Kearney MP
    Infect Control Hosp Epidemiol; 2011 Jun; 32(6):631-3. PubMed ID: 21558782
    [No Abstract]   [Full Text] [Related]  

  • 7. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study.
    Garey KW; Jiang ZD; Bellard A; Dupont HL
    J Clin Gastroenterol; 2009 Jan; 43(1):91-3. PubMed ID: 18385603
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clostridium difficile infections: what is new?].
    Miftode E; Leca D; Dorneanu O
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):656-61. PubMed ID: 22046768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin and Clostridium difficile-associated diarrhoea.
    Golledge CL; Carson CF; O'Neill GL; Bowman RA; Riley TV
    J Antimicrob Chemother; 1992 Aug; 30(2):141-7. PubMed ID: 1399923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection.
    Popovic N; Korac M; Nesic Z; Milosevic B; Urosevic A; Jevtovic D; Pelemis M; Delic D; Prostran M; Milosevic I
    J Infect Dev Ctries; 2015 Oct; 9(10):1062-7. PubMed ID: 26517480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single immunoglobulin infusion can reverse hemodynamic failure associated with severe Clostridium difficile colitis.
    Sokol H; Maury E; Seksik P; Cosnes J; Beaugerie L
    Am J Gastroenterol; 2009 Oct; 104(10):2649-50. PubMed ID: 19806111
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of intravenous immunoglobulin in severe Clostridium difficile-associated diarrhea.
    Shahani L; Koirala J
    Hosp Pract (1995); 2015; 43(3):154-7. PubMed ID: 26189489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.
    Di Bella S; Nisii C; Petrosillo N
    Int J Antimicrob Agents; 2015 Jul; 46(1):8-12. PubMed ID: 25982915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2017 Jul; 53(7):385-392. PubMed ID: 28837182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline as last resort in severe refractory Clostridium difficile infection: a case report.
    Knafl D; Winhofer Y; Lötsch F; Weisshaar S; Steininger C; Burgmann H; Thalhammer F
    J Hosp Infect; 2016 Mar; 92(3):296-8. PubMed ID: 26810610
    [No Abstract]   [Full Text] [Related]  

  • 16. Probiotics for Clostridium difficile diarrhea: putting it into perspective.
    Karpa KD
    Ann Pharmacother; 2007 Jul; 41(7):1284-7. PubMed ID: 17595302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea.
    Wilcox MH
    J Antimicrob Chemother; 2004 May; 53(5):882-4. PubMed ID: 15073160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Bishara J; Wattad M; Paul M
    Clin Infect Dis; 2007 Dec; 45(12):1646-7; author reply 1649-51. PubMed ID: 18190329
    [No Abstract]   [Full Text] [Related]  

  • 20. Fidaxomicin for the treatment of Clostridium difficile infections.
    Drug Ther Bull; 2012 Nov; 50(11):130-2. PubMed ID: 23154594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.